NephroGenex
Founded Year
2004Stage
Asset Sale | AssetsPurchasedTotal Raised
$4.8MAbout NephroGenex
NephroGenex is a pharmaceutical company focused on the development of therapeutics to treat kidney disease, an area of significant unmet medical need. Since its inception, the company has collaborated with experts in kidney disease and leveraged our knowledge of pathogenic oxidative chemistries to build a strong portfolio of intellectual property and to advance the development of our drug candidates. Pathogenic oxidative chemistries, including advanced glycation end-products (AGE's), reactive oxygen species, and toxic carbonyls, are generally agreed to be involved in the etiology of diabetic nephropathy, a common complication of diabetes. The company is developing Pyridorin, a small molecule drug that is a unique and broadly acting inhibitor of the pathogenic oxidative chemistries which are elevated in diabetic patients. The oral form of Pyridorin (pyridoxamine dihydrochloride) is being developed as a drug to slow the progression of diabetic nephropathy. Diabetic nephropathy is a degenerative disease of the kidney caused by diabetes.
Loading...
Loading...
NephroGenex Patents
NephroGenex has filed 4 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
1/25/2008 | 11/29/2011 | Kidney diseases, Diabetes, Nephrology, Kidney anatomy, Syndromes affecting the kidneys | Grant |
Application Date | 1/25/2008 |
|---|---|
Grant Date | 11/29/2011 |
Title | |
Related Topics | Kidney diseases, Diabetes, Nephrology, Kidney anatomy, Syndromes affecting the kidneys |
Status | Grant |
Latest NephroGenex News
Jan 23, 2020
May 18, 2016 The Nasdaq Stock Market announced today that it will delist the common stock Class A of Fairway Group Holdings Corp. Fairway Group Holdings Corp.'s stock was suspended on May 16, 2016 and has not traded on Nasdaq since that time. Nasdaq also announced that it will delist the common stock of QKL Stores, Inc. QKL Stores, Inc.'s stock was suspended on May 12, 2016 and has not traded on Nasdaq since that time. Nasdaq also announced that it will delist the common stock of NephroGenex, Inc. NephroGenex, Inc.'s stock was suspended on May 11, 2016 and has not traded on Nasdaq since that time. Nasdaq also announced that it will delist the common stock of Energy XXI Ltd. Energy XXI Ltd.'s stock was suspended on April 25, 2016 and has not traded on Nasdaq since that time. Nasdaq also announced that it will delist the American Depositary Shares of MOL Global, Inc. MOL Global, Inc.'s stock was suspended on April 18, 2016 and has not traded on Nasdaq since that time. Finally, Nasdaq announced that it will delist the common stock of Ascent Solar Technologies, Inc. Ascent Solar Technologies, Inc.'s stock was suspended on February 25, 2016 Nasdaq will file a Form 25 with the Securities and Exchange Commission to complete the delisting for each of these companies. The delistings become effective ten days after the Form 25 is filed. For news and additional information about the companies, including the basis for the delistings and whether the companies' securities are trading on another venue, please review the companies' public filings or contact the company directly. For more information about The Nasdaq Stock Market , visit the Nasdaq Web site at http://www.nasdaq.com . Nasdaq's rules governing the delisting of securities can be found in the Nasdaq Rule 5800 Series, available on the Nasdaq Web site: http://www.cchwallstreet.com/NasdaqTools/bookmark.asp?id=nasdaq-rule_5800&manual=/nasdaq/main/nasdaq-equityrules/ . NDAQO
NephroGenex Frequently Asked Questions (FAQ)
When was NephroGenex founded?
NephroGenex was founded in 2004.
Where is NephroGenex's headquarters?
NephroGenex's headquarters is located at 79 TW Alexander Drive, Durham.
What is NephroGenex's latest funding round?
NephroGenex's latest funding round is Asset Sale.
How much did NephroGenex raise?
NephroGenex raised a total of $4.8M.
Who are the investors of NephroGenex?
Investors of NephroGenex include Medpace, Vanderbilt University, Karolinska Development, Discovery Life Science Fund, Rho Ventures and 7 more.
Loading...
Loading...